• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
IN THE NEWS | The Call for Rapid, Point-of-Teed Testing Gets Louder

IN THE NEWS | The Call for Rapid, Point-of-Teed Testing Gets Louder

by Oceanit | Sep 24, 2020 | Government, Local News

IN THE NEWS | The Call for Rapid, Point-of-Teed Testing Gets Louder In an opinion piece for the Civil Beat Ideas Section, State Representatives, Bob McDermott (House District 4: Ewa, Ewa Beach, Ewa Gentry and Iroquois Point) and Gene Ward (Hawaii House Minority...
PRESS RELEASE | Oceanit Selected As a Semi-Finalist For the XPRIZE Rapid Covid Testing Competition

PRESS RELEASE | Oceanit Selected As a Semi-Finalist For the XPRIZE Rapid Covid Testing Competition

by Oceanit | Sep 16, 2020 | Future, International News

PRESS RELEASE | Oceanit Selected As a Semi-Finalist For the XPRIZE Rapid Covid Testing Competition Oceanit’s ASSURE-19 Covid-19 test was selected as a semi-finalist from a pool of nearly 700 teams from around the world competing in the XPRIZE Rapid Covid Testing...

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
[dsm_icon_list list_alignment=”flex-end” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” list_alignment_last_edited=”on|phone” list_alignment_phone=”center” sticky_enabled=”0″ list_alignment_tablet=”flex-end”][dsm_icon_list_child text=”Privacy Policy” use_icon=”off” url=”/privacy-policy/” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_text_color=”#e8e8e8″ text_font_size=”12px” text_text_color_last_edited=”off|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#1e73be”][/dsm_icon_list_child][/dsm_icon_list]